Praxis Precision Meds had its Relative Strength (RS) Rating upgraded from 79 to 85 Tuesday.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily identifies price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best-performing stocks often have an RS Rating of over 80 in the early stages of their moves.
Praxis Precision Meds is not currently showing a potential entry point. See if the stock goes on to build a sound pattern that could ignite a new run.
Praxis Precision Meds reported 0% EPS growth last quarter, while sales growth came in at -100%.
The company earns the No. 186 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
